EVOLUTION

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Retrieved on: 
Tuesday, December 5, 2023
Health, Neurology, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Development, ARR, Health care, RMS, EVOLUTION, Caregiver, Safety, Patient, Multiple sclerosis, Science, Pharmaceutical industry, Merck

Of note, teriflunomide ARR values were lower than reported in other recent Phase III studies.

Key Points: 
  • Of note, teriflunomide ARR values were lower than reported in other recent Phase III studies.
  • The overall safety and tolerability profile was consistent with results from the previously reported Phase II trial.
  • The Company will complete a full evaluation of the data from the EVOLUTION clinical trials and will work with investigators on the future presentation and publication of the results.
  • I would like to sincerely thank all patients participating in the trials, their caregivers and our network of dedicated clinical investigators.”

Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Retrieved on: 
Tuesday, December 5, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Merck, Development, ARR, Health care, RMS, Caregiver, EVOLUTION, Safety, Patient, Merck Group, Multiple sclerosis, Pharmaceutical industry

Of note, teriflunomide ARR values were lower than reported in other recent Phase III studies.

Key Points: 
  • Of note, teriflunomide ARR values were lower than reported in other recent Phase III studies.
  • The overall safety and tolerability profile was consistent with results from the previously reported Phase II trial.
  • The Company will complete a full evaluation of the data from the EVOLUTION clinical trials and will work with investigators on the future presentation and publication of the results.
  • I would like to sincerely thank all patients participating in the trials, their caregivers and our network of dedicated clinical investigators.”

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Retrieved on: 
Friday, October 27, 2023
Research, ORY, Fruit, DMC, Food, Deficit spending, Risk, Medicine, ECNP, Schizophrenia, Platinum, ICMJE recommendations, SCLC, Charcot–Marie–Tooth disease, Sciatic nerve, Psychotherapy, Paclitaxel, NET, FCCC, MRD, Safety, EVOLUTION, BPD, Kabuki syndrome, Patient, Borderline personality disorder, ALS, Fox Chase Cancer Center, Genomics, Human, Duration, Glomus tumor, Measure (mathematics), Clinical trial, Dor, DSM-IV codes, Animal, European College of Neuropsychopharmacology, LSD1, FMS, CMT, FDA, IND, Innovation, ISIN, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, HOPE, AML, Failure, Medical device, Pharmaceutical industry, Nursing, Cryptocurrency, EU, Science

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
  • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
  • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
  • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

Carrera Celebrates 60 Years of Racing Fun Driven by Nostalgia

Retrieved on: 
Thursday, February 9, 2023
Evolution, DTM, PAW Patrol, Red Bull, Freedom, DIGITAL, Hertz, Movement, EVOLUTION, 2012 Super GT Series, Dog, Cassette tape, Toy

EAST BRUNSWICK, N.J., Feb. 9, 2023 /PRNewswire/ -- Carrera, the world market leader in the slot car segment is celebrating its 60-year anniversary. Founded in 1963, Carrera has continued to captivate generations of passionate racing fans with thrilling racing experiences. Even today, 60 years later. 

Key Points: 
  • Founded in 1963, Carrera has continued to captivate generations of passionate racing fans with thrilling racing experiences.
  • At Carrera, generations of families have experienced fast duels and action-packed drifts together at the Carrera racecourse, and with numerous product innovations and further developments, every Carrera car race is remembered.
  • The youngest Carrera friends can start racing at three years old on the blue Carrera FIRST track.
  • In 1963, Carrera laid the foundation for the "Carrera Universal" system on a scale of 1:32, continuing the success story four years later with the "Carrera 124" system.

PANDORUM INTERNATIONAL ENGAGES EVOLUTION LIFE SCIENCE PARTNERS

Retrieved on: 
Wednesday, January 18, 2023
EVOLUTION, M&A, Liver, Regeneration, PANDORUM, Regenerative medicine, Partnership, Therapy, SAN, Exosome, USFDA, Pharmaceutical industry

SAN CARLOS, Calif., Jan. 18, 2023 /PRNewswire/ -- PANDORUM International Inc. has engaged EVOLUTION Life Science Partners to assist the company in raising capital to fund the ongoing development of its assets, primarily Bioengineered Liquid Cornea, advanced therapeutics to promote cornea regeneration.

Key Points: 
  • SAN CARLOS, Calif., Jan. 18, 2023 /PRNewswire/ -- PANDORUM International Inc. has engaged EVOLUTION Life Science Partners to assist the company in raising capital to fund the ongoing development of its assets, primarily Bioengineered Liquid Cornea, advanced therapeutics to promote cornea regeneration.
  • The company is also exploring licensing and M&A opportunities of its assets with various pharmaceutical organizations, with the assistance from EVOLUTION.
  • EVOLUTION Life Science Partners is a life science investment bank that specializes in licensing, strategic advisory, M&A, and capital raising.
  • To learn more about EVOLUTION, visit www.evolutionlsp.com
    PANDORUM International Inc. is a regenerative medicine company with proprietary tissue regeneration platform.

PANDORUM INTERNATIONAL ENGAGES EVOLUTION LIFE SCIENCE PARTNERS

Retrieved on: 
Wednesday, January 18, 2023
EVOLUTION, M&A, Liver, Regeneration, PANDORUM, Regenerative medicine, Partnership, Therapy, SAN, Exosome, USFDA, Pharmaceutical industry

SAN CARLOS, Calif., Jan. 18, 2023 /PRNewswire/ -- PANDORUM International Inc. has engaged EVOLUTION Life Science Partners to assist the company in raising capital to fund the ongoing development of its assets, primarily Bioengineered Liquid Cornea, advanced therapeutics to promote cornea regeneration.

Key Points: 
  • SAN CARLOS, Calif., Jan. 18, 2023 /PRNewswire/ -- PANDORUM International Inc. has engaged EVOLUTION Life Science Partners to assist the company in raising capital to fund the ongoing development of its assets, primarily Bioengineered Liquid Cornea, advanced therapeutics to promote cornea regeneration.
  • The company is also exploring licensing and M&A opportunities of its assets with various pharmaceutical organizations, with the assistance from EVOLUTION.
  • EVOLUTION Life Science Partners is a life science investment bank that specializes in licensing, strategic advisory, M&A, and capital raising.
  • To learn more about EVOLUTION, visit www.evolutionlsp.com
    PANDORUM International Inc. is a regenerative medicine company with proprietary tissue regeneration platform.

ORYZON to Give Updates on Corporate Progress in November

Retrieved on: 
Friday, November 4, 2022
EVOLUTION, Pipeline, Medulloblastoma, ISIN, ESCAPE, CNS, Clinical trial, Government budget balance, Schizophrenia, Degenerative disease, Hematological Cancer Research Investment and Education Act, Prospectus, Borderline personality disorder, Moderate, GLOBE, Mouse, IND, FLT3, NCI, NET, EHA, COVID-19, Mission statement, Forward-looking statement, CRADA, Patient, Cancer, ORY, Kabuki syndrome, Azacitidine, MS, Sale, Spanish, Multiple sclerosis, ESMO, Cooperative research and development agreement, LSD1, Aggression, Genomics, Market, Mercado, Time, Wilms' tumor, SCLC, Squamous cell carcinoma, Ageing, Safety, Conference, Neuroinflammation, CNMV, ALICE, AD, Development, Syndrome, Public expenditure, AML, Person, Communication, Amnesia, Pharmaceutical industry, EU

Oryzon will participate at the Inv€$tival Showcase LSX Leaders 2022 conference, which will be held on November 14 in London (United Kingdom). The company will take part in a panel entitled “CNS and the Market -- What is New in the Pipeline and in Deal Activity?”on November 14 at 15:00 local time. Click on link for more info about the Inv€$tival Showcase LSX Leaders conference

Key Points: 
  • Oryzons medical team will participate at the Kabuki Syndrome Foundation Annual Conference, which will be held virtually on November 4.
  • In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases.
  • Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon.
  • This press release is not an offer of securities for sale in the United States or any other jurisdiction.

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

Retrieved on: 
Friday, September 16, 2022
Adult, Multiple sclerosis, Safety, CNMV, EVOLUTION, EudraCT, Ageing, AD, Data monitoring committee, Aggression, Mercado, Amnesia, Patient, Clinical trial, Suicide, Government budget balance, Communication, Time, ISIN, ORY, Sale, Mouse, Person, Public expenditure, Lists of diseases, Prospectus, Neuroinflammation, Particle-size distribution, Borderline personality disorder, COVID-19, Degenerative disease, Forward-looking statement, ESCAPE, Genomics, BPD, GLOBE, Spanish, Agitation, Conference, Mission statement, LSD1, Self-harm, Schizophrenia, Program, MS, Mental health, Moderate, Kabuki syndrome, CNS, BDP, Pharmaceutical industry, Phase

Blinded aggregate safety data presented at ECMH correspond to the initial randomized 43 patients (data cut-off, 30 June 2022).

Key Points: 
  • Blinded aggregate safety data presented at ECMH correspond to the initial randomized 43 patients (data cut-off, 30 June 2022).
  • In July 2022, the independent Data Monitoring Committee for PORTICO reviewed the available safety data and determined that the trial should continue.
  • Oryzons oral communication at ECMH is entitled PORTICO, a double-blind, randomized placebo-controlled, adaptive Phase IIb trial with vafidemstat in Borderline Personality Disorder.
  • Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION).

ORYZON to Give Updates on Corporate Progress in June

Retrieved on: 
Monday, June 6, 2022
Public expenditure, EST, Mission statement, Congress, Time, Lists of diseases, Government budget balance, Spanish, FLT3, Jefferies, Hematological Cancer Research Investment and Education Act, CNMV, Amnesia, IND, Sale, Ageing, Cancer, LSX, Borderline personality disorder, Forward-looking statement, Neuroinflammation, Mercado, Degenerative disease, Person, Moderate, Acute myeloid leukemia, Mouse, SCLC, CNS, ALICE, Communication, Genomics, Aggression, COVID-19, ESCAPE, ESMO, AML, European Hematology Association, Patient, AD, Schizophrenia, Medulloblastoma, Multiple sclerosis, Azacitidine, Wilms' tumor, LSD1, NET, ASH, EVOLUTION, ISIN, GLOBE, MS, Prospectus, ORY, Clinical trial, Squamous cell carcinoma, Kabuki syndrome, Safety, Pharmaceutical industry, Fine chemical

Oryzon will participate at the Jefferies Healthcare 2022 conference, which will be held on June 8-10 in New York (USA).

Key Points: 
  • Oryzon will participate at the Jefferies Healthcare 2022 conference, which will be held on June 8-10 in New York (USA).
  • The company will provide a corporate update on June 10 at 12:45 pm EST and will also hold one-to-one meetings with pharmaceutical companies and global investors.
  • In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases.
  • Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon.